Compare · BIIB vs SLXN
BIIB vs SLXN
Side-by-side comparison of Biogen Inc. (BIIB) and Silexion Therapeutics Corp (SLXN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BIIB and SLXN operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- BIIB is the larger of the two at $28.93B, about 14207.5x SLXN ($2.0M).
- Over the past year, BIIB is up 48.7% and SLXN is down 96.6% - BIIB leads by 145.2 points.
- SLXN has been more active in the news (17 items in the past 4 weeks vs 9 for BIIB).
- BIIB has more recent analyst coverage (25 ratings vs 0 for SLXN).
- Company
- Biogen Inc.
- Silexion Therapeutics Corp
- Price
- $196.01+3.80%
- $4.85-0.82%
- Market cap
- $28.93B
- $2.0M
- 1M return
- +4.69%
- -24.34%
- 1Y return
- +48.65%
- -96.60%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- News (4w)
- 9
- 17
- Recent ratings
- 25
- 0
Biogen Inc.
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB111 and BIIB112 to treat ophthalmology related diseases; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and TMS-007 to treat acute neurology; BIIB074 and BIIB095 for neuropathic pain; and SB11 and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Bristol-Myers Squibb Company; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Ginkgo Bioworks; Capsigen Inc.; and Mirimus, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Latest BIIB
- Biogen Announces Upcoming Kidney Presentations at European Renal Association and American Transplant Congresses
- UCB and Biogen Announce Publication in The Lancet of Positive Dapirolizumab Pegol (DZP) Phase 3 Study Results in Systemic Lupus Erythematosus
- Stoke Therapeutics to Present at Upcoming Investor Conferences in June
- Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson's Disease
- BIIB SHAREHOLDER INVESTIGATION: SueWallSt Investigates Biogen Inc. for Possible Securities Law Violations
- Evercore ISI resumed coverage on Biogen
- Biogen Completes Acquisition of Apellis Pharmaceuticals
- Biogen Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Regulation FD Disclosure, Financial Statements and Exhibits
- Topline Results from Phase 2 CELIA Study of Diranersen (BIIB080): First Study to Show Reduction in Tau Pathology and Cognitive Benefit in Patients with Early Alzheimer's Disease
- Update on FDA Priority Review of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection as a Starting Dose for Early Alzheimer's Disease
Latest SLXN
- SEC Form PRE 14A filed by Silexion Therapeutics Corp
- Amendment: SEC Form SCHEDULE 13D/A filed by Silexion Therapeutics Corp
- Silexion Therapeutics Corp filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits
- SEC Form S-8 filed by Silexion Therapeutics Corp
- Silexion Therapeutics Corp filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Silexion Therapeutics Announces 1-for-10 Reverse Share Split
- Amendment: SEC Form 10-K/A filed by Silexion Therapeutics Corp
- Silexion Therapeutics Corp filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Silexion Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
- SEC Form 10-Q filed by Silexion Therapeutics Corp